Trial Profile

A Phase 3 Study to Evaluate NTCD-M3 for the Prevention of C. Difficile Infection (CDI) Recurrence

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NTCD M3 (Primary)
Indications Clostridium difficile infections
Focus Registrational; Therapeutic Use
Sponsors Destiny Pharma

Most Recent Events

24 Feb 2023 According to a Destiny Pharma media release, company will provide a live presentation via the Investor Meet Company platform on 27 Feb 2023 at 10.00am GMT.
24 Feb 2023 According to a Destiny Pharma media release, company partnered with Sebela Pharmaceuticals to advance this trial and plan for commercialization in US NTCD-M3.
24 Feb 2023 According to a Destiny Pharma media release, company anticipates this study will commence in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com